Infants diagnosed with Fragile X syndrome face a future marked by cognitive decline, speech impairment, heightened anxiety, hyperactivity, irritability, and impulsivity. Current treatments are piecemeal and riddled with side effects.
Seropeutics develops efficacious therapies addressing the needs of Fragile X syndrome, and has identified two promising candidates, SERx – 519 and SERx – 480, that ameliorate core symptoms while measurably reducing side effects.
Executive Chairman & CEO
Scientific Founder and Chief Scientist
For more information about Seropeutics, contact Donald Kiepert.